Literature DB >> 33131073

The role of Dipeptidyl Peptidase-4 in cutaneous disease.

Payal M Patel1, Virginia A Jones1, Khalaf Kridin2, Kyle T Amber1.   

Abstract

Dipeptidyl peptidase-4 (DPP4) is a multifunctional, transmembrane glycoprotein present on the cell surface of various tissues. It is present in multiple molecular forms including cell surface and soluble. The role of DPP4 and its inhibition in cutaneous dermatoses have been a recent point of investigation. DPP4 exerts a notable influence on T-cell biology, the induction of skin-specific lymphocytes, and the homeostasis between regulatory and effector T cells. Moreover, DPP4 interacts with a broad range of molecules, including adenosine deaminase, caveolin-1, CXCR4 receptor, M6P/insulin-like growth factor II-receptor and fibroblast activation protein-α, triggering downstream effects that modulate the immune response, cell adhesion and chemokine activity. DPP4 expression on melanocytes, keratinocytes and fibroblasts further alters cell function and, thus, has crucial implications in cutaneous pathology. As a result, DPP4 plays a significant role in bullous pemphigoid, T helper type 1-like reactions, cutaneous lymphoma, melanoma, wound healing and fibrotic disorders. This review illustrates the multifactorial role of DPP4 expression, regulation, and inhibition in cutaneous diseases.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Dipeptidyl Peptidase-4; autoimmunity; cancer; inflammatory skin diseases; wound healing

Mesh:

Substances:

Year:  2020        PMID: 33131073     DOI: 10.1111/exd.14228

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  8 in total

1.  Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes.

Authors:  Lei Bao; Jing Li; Bethany E Perez White; Payal M Patel; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-05       Impact factor: 3.033

2.  Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS.

Authors:  Farzan Solimani; Dario Didona; Jing Li; Lei Bao; Payal M Patel; Giulia Gasparini; Khalaf Kridin; Emanuele Cozzani; Michael Hertl; Kyle T Amber
Journal:  Arch Dermatol Res       Date:  2021-06-21       Impact factor: 3.033

3.  CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study.

Authors:  Pietro Quaglino; Mauro Novelli; Paolo Fava; Erika Ortolan; Chiara Astrua; Luca Tonella; Carlo Francesco Tomasini; Rebecca Senetta; Simone Ribero; Renata Ponti; Maria Teresa Fierro; Ada Funaro
Journal:  Dis Markers       Date:  2022-02-24       Impact factor: 3.434

4.  Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Yuichiro Iwamoto; Takatoshi Anno; Katsumasa Koyama; Fumiko Kawasaki; Kohei Kaku; Koichi Tomoda; Seiko Sugiyama; Yumi Aoyama; Hideaki Kaneto
Journal:  Front Immunol       Date:  2022-03-03       Impact factor: 7.561

5.  Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.

Authors:  Antti Nätynki; Päivi Leisti; Jussi Tuusa; Outi Varpuluoma; Laura Huilaja; Kentaro Izumi; Sanna-Kaisa Herukka; Olavi Ukkola; Juhani Junttila; Nina Kokkonen; Kaisa Tasanen
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 6.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 7.  Immunological aspects of COVID-19-related skin manifestations: Revisiting pathogenic mechanism in the light of new evidence.

Authors:  Sara Mahdiabadi; Fateme Rajabi; Soheil Tavakolpour; Nima Rezaei
Journal:  Dermatol Ther       Date:  2022-08-26       Impact factor: 3.858

Review 8.  Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity?

Authors:  Xin Huang; Yimin Khoong; Chengyao Han; Dai Su; Hao Ma; Shuchen Gu; Qingfeng Li; Tao Zan
Journal:  Front Physiol       Date:  2021-07-15       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.